In the global phase II study (NCT01897571), patients with relapsed/refractory follicular lymphoma (FL) achieved an objective response rate (ORR) of 69% (95% confidence interval [CI] 53%–82%; 31 of 45 patients) in the mutant EZH2 cohort and 35% (95% CI 23%–49%; 19 of 54 patients) in the wild-type EZH2 cohort (median follow-up period of 22.0 months) [3]. Here, EZH2 is linked to follicular lymphoma.